title: Comparison of the aneugenic properties of nocodazole, paclitaxel and griseofulvin in vitro. Centrosome defects and alterations in protein expression profiles.
abstract: We have comparatively investigated the aneugenic activity of two anticancer drugs, nocodazole (NOC) and paclitaxel (PTX), and the antifungal griseofulvin with promising role in cancer treatment (GF), which affect microtubule dynamics in different ways. The comparison was achieved in HFFF2 human fibroblasts, MCF-7 human breast cancer cells and C2C12 mouse myoblasts, and focused on three issues: (i) induction of chromosome delay by estimation of MN frequency using CREST analysis; (ii) disturbance of spindle organization with Aurora-A/β-tubulin immunofluorescence; and (iii) alterations in the expression of Aurora-A, β- and γ-tubulin by western blotting. They induced chromosome delay, provoked metaphase arrest and promoted microtubule disorganization, reflecting their common characteristic of generating aneuploidy. In particular, NOC induced mainly monopolar metaphases, although PTX induced only multipolar metaphases. GF generated different types of abnormal metaphases, exhibiting cell specificity. Additionally, NOC decreased the expression of Aurora-A and β-tubulin, while the opposite held true for PTX and GF. γ-Tubulin expression was not modulated owing to NOC treatment, whereas PTX and GF increased γ-tubulin expression. Our findings throw a light on the manifestation of the aneugenicity of the studied compounds through centrosome proliferation/separation and protein expression, reflecting their different effects on microtubule dynamics.
authors.affiliation: Division of Genetics, Cell and Developmental Biology, Department of Biology, University of Patras, 26 500, Patras, Greece.
authors.forename: Polyxeni
authors.initials: P
authors.lastname: Zacharaki
authors.forename: Georgia
authors.initials: G
authors.lastname: Stephanou
authors.forename: Nikos A
authors.initials: NA
authors.lastname: Demopoulos
mesh_terms: D024422:Aneugens / Q000494:pharmacology*; D000782:Aneuploidy; D000818:Animals; D000935:Antifungal Agents / Q000633:toxicity; D000970:Antineoplastic Agents / Q000633:toxicity; D017209:Apoptosis / Q000187:drug effects; D002453:Cell Cycle / Q000187:drug effects; D018385:Centrosome / Q000187:drug effects* / Q000473:pathology; D005347:Fibroblasts / Q000187:drug effects; D005455:Fluorescent Antibody Technique; D006118:Griseofulvin / Q000494:pharmacology*; D006801:Humans; D007399:Interphase / Q000187:drug effects; D061986:MCF-7 Cells; D008677:Metaphase / Q000187:drug effects; D051379:Mice; D008870:Microtubules / Q000187:drug effects / Q000378:metabolism; D032446:Myoblasts / Q000187:drug effects; D015739:Nocodazole / Q000494:pharmacology*; D017239:Paclitaxel / Q000494:pharmacology*; D059467:Transcriptome / Q000187:drug effects*; D014404:Tubulin / Q000235:genetics / Q000378:metabolism
chemical_list: D024422:Aneugens; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D014404:Tubulin; D006118:Griseofulvin; D017239:Paclitaxel; D015739:Nocodazole